Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents

Phase 1b Trial Evaluating Idelalisib in Children and Adolescents With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Mediastinal B-cell Lymphoma in Combination With RICE

The primary objectives of this study are to evaluate safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of idelalisib; and to establish recommended phase 2 doses (RP2D) of idelalisib in combination with rituximab, ifosfamide, carboplatin, etoposide (RICE) in children and adolescents with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or mediastinal B-cell lymphoma (MBCL)

Study Overview

• Status: Withdrawn
• Conditions: Diffuse Large B-Cell Lymphoma; Mediastinal B-cell Lymphoma
• Intervention / Treatment: Drug: Idelalisib; Drug: Rituximab; Drug: Ifosfamide; Drug: Carboplatin; Drug: Etoposide

• Study Type: Interventional
• Phase: Phase 1

Contacts and Locations

Study Locations

• France
  • Lille, France, 59000
    • Centre Hospitalier Regional Universitaire de Lille
• Italy
  • Genova, Italy, 16147
    • Istituto Giannina Gaslini
  • Roma, Italy, 00165
    • Ospedale Pediatrico Bambino Gesù
  • Torino, Italy, 10126
    • Infantile Regina Margherita Hospital
• Poland
  • Wrocław, Poland, 50-556
    • Uniwersytecki Szpital Kliniczny Im. Jana Mikulicza-Radeckiego We Wroclawiu
• Spain
  • Barcelona, Spain, 08035
    • Hospital Vall d´hebron
  • Madrid, Spain, 28660
    • Hospital Universitario HM Monteprincipe

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 year to 18 years (Child, Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Key Inclusion Criteria:

• Histologically confirmed diagnosis of DLBCL or MBCL established by the World Health Organization (WHO) 2008 classification of tumors of hematopoietic and lymphoid tissues
• Relapsed or refractory disease
• Measurable or evaluable disease based on imaging or bone marrow examination
• Karnofsky ≥ 60% for participants > 16 years of age or Lansky ≥ 60 for participants ≤ 16 years of age. Participants who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
• A negative serum pregnancy test is required for females of child bearing potential.
• Participants of child bearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception .
• Lactating females must agree to discontinue nursing before idelalisib is administered
• Adequate bone marrow function as defined in the protocol
• Adequate renal function as defined in the protocol

Key Exclusion Criteria:

• Prior ifosfamide, carboplatin, etoposide (ICE) therapy, with or without an anti-CD20 antibody, or history of hypersensitivity to any components of RICE
• Known active central nervous system or leptomeningeal lymphoma or within 4 weeks from the last intrathecal therapy prior to the required diagnostic lumbar puncture (LP) for this study
• Disease progression within 6 months from last anti-CD20 therapy
• Ongoing toxicity from prior cytotoxic therapy (last dose at least 3 weeks prior to study entry)
• Less than 4 half-lives from the last dose of previous targeted therapy and ongoing acute toxicity of prior targeted therapy
• Active infection with human immunodeficiency virus (HIV), cytomegalovirus (CMV), hepatitis B virus (HBV), or hepatitis C virus (HCV) based on screening serology and polymerase chain reaction (PCR) results
• Evidence of systemic bacterial, fungal, or viral infection at the time of treatment start (Day 1)
• Ongoing or history of drug-induced pneumonitis
• Ongoing or history of inflammatory bowel disease
• Pregnancy or breastfeeding
• Currently receiving other anti-cancer or other investigational drug
• Prior solid organ transplantation
• Prior allogeneic stem cell transplantation within 60 days or active acute graft versus host disease (GVHD) Grade 3 or higher
• Known hypersensitivity to idelalisib, the metabolites, or formulation excipients
• Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the participant unsuitable for the study or unable to comply with the study requirements

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort 1- Participants 12 to less than 18 years of age; Participants will receive idelalisib monotherapy (from day 1 to day 21), followed by combination therapy with RICE. Upon enrollment, participants will be assigned to one of the 3 dose levels during idelalisib monotherapy (Dose level 1 = 55 mg/m^2 twice daily (BID), Dose level 2 = 85 mg/m^2 BID, Dose level 3 = 125 mg/m^2 BID) administered as 50 mg, 100 mg or 150 mg tablets as appropriate, or as 10 mg dispersible tablets for oral suspension for participants who cannot swallow tablets.; Day 1: single dose of idelalisib; Day 2 up to Day 21: initiate and continue idelalisib BID dosing; Day 22 for up to 12 months: idelalisib twice per day in combination with RICE. Cycles of RICE will be administered over 5 days every 3 weeks (Day 1: rituximab; Day 3: rituximab, ifosfamide, carboplatin, etoposide; Days 4 and 5: ifosfamide, etoposide) starting day 22 (or earlier if there is evidence of clinical progression while on idelalisib monotherapy) for up to 12 months.	Drug: Idelalisib; Tablet (s) or dispersible tablets for suspension administered orally twice daily; Other Names: Zydelig®; Drug: Rituximab; 375 mg/m^2 administered intravenously; Drug: Ifosfamide; 3 mg/m^2 administered intravenously; Drug: Carboplatin; 635 mg/m^2 administered intravenously; Drug: Etoposide; 100 mg/m^2 administered intravenously
Experimental: Cohort 2- Participants 1 to less than 12 years of age; Participants will receive one of the 3 doses of idelalisib monotherapy (from day 1 to day 21) followed by combination therapy with RICE. Idelalisib will be administered as as 50 mg, 100 mg or 150 mg tablets as appropriate, or as 10 mg dispersible tablets for oral suspension for participants who cannot swallow tablets. Participants will will be enrolled at dose level 1 once tolerability is demonstrated in the older cohort (Cohort 1). Thereafter, both age cohorts will be dose escalated independently.; Day 1: single dose of idelalisib; Day 2 up to Day 21: initiate and continue idelalisib BID; Day 22 for up to 12 months: idelalisib twice per day in combination with RICE. Cycles of RICE will be administered over 5 days every 3 weeks (Day 1: rituximab; Day 3: rituximab, ifosfamide, carboplatin, etoposide; Days 4 and 5: ifosfamide, etoposide) starting day 22 (or earlier if there is evidence of clinical progression while on idelalisib monotherapy) for up to 12 months.	Drug: Idelalisib; Tablet (s) or dispersible tablets for suspension administered orally twice daily; Other Names: Zydelig®; Drug: Rituximab; 375 mg/m^2 administered intravenously; Drug: Ifosfamide; 3 mg/m^2 administered intravenously; Drug: Carboplatin; 635 mg/m^2 administered intravenously; Drug: Etoposide; 100 mg/m^2 administered intravenously

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence Rate of Dose Limiting Toxicities (DLTs)	DLTs refer to toxicities experienced during the first 21 days of study treatment that have been judged to be clinically significant and related to study treatment.	Up to Day 21
Proportion of Participants Experiencing Adverse Events (AEs)		Up to 12 months
Proportion of Participants Experiencing Serious Adverse Events (SAEs)		Up to 12 months
Proportion of Participants Experiencing Adverse Events (AEs) Leading to Idelalisib Interruption, Idelalisib Dose Reduction, Premature Discontinuation of Idelalisib, or Death		Up to 12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of Grade ≥ 3 Transaminase Elevations Based on Laboratory Findings		Up to 12 months
Overall Response Rate (ORR)	Overall response rate (ORR) is defined as the proportion of participants who achieve a best response of Complete Response (CR) or Partial Response (PR) after the first dose of idelalisib (either as a result of monotherapy or in combination with RICE chemoimmunotherapy). The screening imaging study will serve as the reference for ORR.	Up to 12 months
Overall Survival (OS)	Overall Survival (OS) is defined as the interval from the first dose date of idelalisib to death from any cause.	Up to 5 years
Progression-Free Survival (PFS)	Progression-Free Survival (PFS) is defined as the interval from the start date of RICE to the earlier of the first documentation of disease progression or death from any cause. Computed tomography/ magnetic resonance imaging (CT/MRI) scan at the conclusion of idelalisib monotherapy will serve as the reference for progression.	Up to 12 months
Pharmacokinetic Parameter: Cmax of Idelalisib	Cmax is defined as the maximum observed concentration of drug.	Predose and up to 24 hours postdose on Day 1 and Cycle 1, Day 5 of idelalisib + RICE combination therapy
Pharmacokinetic Parameter: Cmax of GS-563117	GS-563117 is the metabolite of idelalisib. Cmax is defined as the maximum observed concentration of drug.	Predose and up to 24 hours postdose on Day 1 and Cycle 1, Day 5 of idelalisib + RICE combination therapy
Pharmacokinetic Parameter: Ctrough of Idelalisib	Ctrough is defined as the plasma concentration at the end of the dosing interval.	Predose and up to 24 hours postdose on Day 1 and Cycle 1, Day 5 of idelalisib + RICE combination therapy
Pharmacokinetic Parameter: Ctrough of GS-563117	Ctrough is defined as the plasma concentration at the end of the dosing interval.	Predose and up to 24 hours postdose on Day 1 and Cycle 1, Day 5 of idelalisib + RICE combination therapy
Pharmacokinetic Parameter: Area Under the Concentration-Time Curve (AUC) of Idelalisib	AUC is defined as the plasma concentration at the end of the dosing interval.	Predose and up to 24 hours postdose on Day 1 and Cycle 1, Day 5 of idelalisib + RICE combination therapy
Pharmacokinetic Parameter: Area Under the Concentration-Time Curve (AUC) of GS-563117	AUC is defined as the plasma concentration at the end of the dosing interval.	Predose and up to 24 hours postdose on Day 1 and Cycle 1, Day 5 of idelalisib + RICE combination therapy
Levels of Optional Exploratory Biomarkers on Bone Marrow Samples (eg pAKT, pS6 ribosomal protein) and plasma cytokines		Baseline and Day 21
Acceptability and Palatability of Idelalisib 10-mg Dispersible Tablet	For participants who cannot swallow a whole tablet, the investigator will ask if the tablet administered as a suspension is palatable and will observe if the participant is able to swallow the dosage form. The acceptability and palatability of idelalisib dispersible tablets administered as an oral suspension (for participants unable to swallow the tablet) will be evaluated by a questionnaire administered to the participant and/or the parent/legal guardian.	Day 1 of idelalisib monotherapy and at Day 1, Cycle 1 of idelalisib in combination with RICE chemoimmunotherapy

Collaborators and Investigators

• Sponsor: Gilead Sciences

Study record dates

Study Major Dates

• Study Start (Anticipated): June 1, 2019
• Primary Completion (Anticipated): February 1, 2021
• Study Completion (Anticipated): February 1, 2026

Study Registration Dates

• First Submitted: November 17, 2017
• First Submitted That Met QC Criteria: November 17, 2017
• First Posted (Actual): November 21, 2017

Study Record Updates

• Last Update Posted (Actual): December 11, 2018
• Last Update Submitted That Met QC Criteria: December 7, 2018
• Last Verified: December 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antirheumatic Agents; Antineoplastic Agents; Immunologic Factors; Antineoplastic Agents, Alkylating; Alkylating Agents; Antineoplastic Agents, Phytogenic; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Antineoplastic Agents, Immunological; Carboplatin; Etoposide; Ifosfamide; Rituximab; Idelalisib
• Other Study ID Numbers: GS-US-313-1090; 2017-001468-39 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes